Connor, Clark & Lunn Investment Management (CC&L)
ASMB icon

Connor, Clark & Lunn Investment Management (CC&L)’s Assembly Biosciences ASMB Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$653K Buy
23,765
+2,004
+9% +$54.6K ﹤0.01% 1311
2026
Q1 		$604K Buy
21,761
+959
+5% +$27.4K ﹤0.01% 1274
2025
Q4 		$707K Buy
20,802
+9,646
+86% +$311K ﹤0.01% 1229
2025
Q3 		$286K Buy
+11,156
New +$245K ﹤0.01% 1370
2025
Q2 		– Sell
-10,182
Closed -$97.3K – 1501
2025
Q1 		$97.3K Sell
10,182
-631
-6% -$8.25K ﹤0.01% 1352
2024
Q4 		$171K Buy
+10,813
New +$174K ﹤0.01% 1340
2023
Q1 		– Sell
-5,449
Closed -$85K – 1236
2022
Q4 		$85K Sell
5,449
-5,364
-50% -$91.7K ﹤0.01% 1121
2022
Q3 		$213K Sell
10,813
-1,097
-9% -$26.5K ﹤0.01% 986
2022
Q2 		$300K Sell
11,910
-1,836
-13% -$42.3K ﹤0.01% 864
2022
Q1 		$340K Sell
13,746
-439
-3% -$9.43K ﹤0.01% 848
2021
Q4 		$397K Buy
14,185
+1,150
+9% +$37.7K ﹤0.01% 842
2021
Q3 		$544K Buy
13,035
+395
+3% +$16.6K ﹤0.01% 756
2021
Q2 		$589K Buy
12,640
+1,078
+9% +$53.4K ﹤0.01% 760
2021
Q1 		$638K Buy
+11,562
New +$766K ﹤0.01% 761
2020
Q2 		– Sell
-1,333
Closed -$237K – 1007
2020
Q1 		$237K Buy
+1,333
New +$286K ﹤0.01% 840

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ASMB Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Assembly Biosciences (ASMB) stake by 9.2% in Q2 2026, buying an estimated $54.6K and bringing the position to 23,765 shares worth $653K. The position accounts for ﹤0.01% of the portfolio, ranked #1311.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ASMB in Q1 2020 and has held it in 15 quarters since. The position peaked at $707K in Q4 2025. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 23,765 shares of Assembly Biosciences worth $653K as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 2,004 Assembly Biosciences shares in Q2 2026, an estimated $54.6K.
  • Assembly Biosciences made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1311 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Assembly Biosciences in Q1 2020 and has held it in 15 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Assembly Biosciences position peaked at $707K in Q4 2025.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.